EUVIMED · CrossrefJournal
Hepatoma Research
ISSN 2454-2520 · OAE Publishing Inc.
Latest articles
Non-invasive assessment in MASLD: from biomarker discovery to clinical pathway integration
Biological significance and translational challenges of circPICALM RNA and its encoded protein circPICALM-219aa in cholangiocarcinoma
Exploratory whole-tumor and habitat radiomic associations with study-documented Clonorchis sinensis status in hepatocellular carcinoma
Prognostic factors and a Cox proportional hazards model for survival in primary liver cancer
Mechanisms and therapeutic implications of interactions between the gut microbiome and host epigenetics in hepatocellular carcinoma
Advancing immunotherapy and tumor microenvironment research in hepatocellular carcinoma
Beyond scarcity: rethinking transplant candidacy in the era of pig-to-human liver xenotransplantation
From gut-liver axis hijacking to intratumoral microbiota establishment: mechanisms and therapeutic opportunities in hepatocellular carcinoma
Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?
Evolving epidemiology and antimicrobial resistance in cirrhosis: time for a region-specific approach
Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside
Pseudocirrhosis: pathophysiology, clinical mimics, and its role in hepatocellular carcinoma diagnosis and management
Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease
From platforms to pathways: imaging innovation, quantitative biomarkers, and clinical translation in hepatocellular carcinoma
Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma
When a hazard ratio is not enough: non-proportional hazards are reshaping the interpretation of phase III trials in hepatocellular carcinoma
Malnutrition in MASLD-related hepatocellular carcinoma: assessment limitations, multidimensional mechanisms, and microbiome-based interventions
Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - mechanisms, clinical evidence, and therapeutic perspectives
Precision medicine in metabolic dysfunction-associated steatotic liver disease: genetics, epigenetics, and emerging therapies
From algorithm to dialogue: interpreting the 2026 BCLC-CUSE strategy for HCC care
Multidisciplinary management of HCC
Gut microbiota as predictors of immunotherapy response in hepatocellular carcinoma
Hepatocellular carcinoma tumor immune microenvironment: heterogeneity and therapeutic strategies
A review on decellularization scaffolding for liver regeneration in transplantation
A systematic review of comparative economic analyses of systemic therapies for hepatocellular carcinoma
Regional dietary patterns and risk of primary liver cancer in anhui, china: a population-based case-control study
An activated CD8+ T cell-based signature stratifies prognosis and suggests differential sensitivity to immune checkpoint inhibitors in hepatocellular carcinoma
Helicobacter pylori is associated with a higher risk of MAFLD prevalence and all-cause mortality: results from the NHANES III follow-up study
Targeting gut microbiota to overcome immunotherapy resistance in hepatocellular carcinoma: from mechanisms to clinical practice
Incretin-based therapies: a new era in metabolic liver disease management
EUVIMED